| Name | Tissue Regenix Group |
|---|---|
| Epic | TRX |
| Isin | GB00BNTXR104 |
| Industry | Investment Banking and Brokerage Services |
| Latest share price | 61.20p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £43.69 | Debt ratio | n/a |
| Shares in issue | 70.57 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -1.64 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -2.43 | 52-week high / low | 50.40p / 74.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Tissue Regenix Group |
|---|---|
| Address | Unit 3, Phoenix Court, Lotherton Way, Garforth, United Kingdom, LS25 2GY |
| Telephone | +44 (0) 1904 567 609 |
| Website | http://www.tissueregenix.com/ |
| Director | Position |
|---|---|
| Mr Daniel Lee | CEO |
| Mr David Cocke | CFO |
| Professor Shervanthi Homer - Vanniasinkam | Non-Executive Director |
| Mr Jonathan Glenn | Non-Executive Chairman |
| Mr Brian Phillips | Independent Non-Executive Director |
| Dr Trevor Phillips | Independent Non-Executive Director |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 15.13 | 15.06 | 15.06 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 24.15 | 24 | 24.16 |
| Inventory / work in progress | 10.36 | 10.88 | 9.72 |
| Trade and other receivables | 3.73 | 4.8 | 4.1 |
| Cash and equivalents | 4.65 | 5.95 | 7.71 |
| Other current assets and asset held for resale | 0.35 | 0.4 | 0.53 |
| Total of all assets | 43.24 | 46.04 | 46.22 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 4.73 | 6.64 | 4.36 |
| Long term liabilities | 9.15 | 8.99 | 8.47 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 13.89 | 15.64 | 12.83 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 29.36 | 30.4 | 33.39 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 15.95 | 15.95 | 15.95 |
| Minority interests | -0.8 | -0.85 | -0.95 |
| Retained earnings | -123.76 | -122.13 | -120.43 |
| Share premium account | 134.25 | 134.18 | 134.17 |
| Total equity | 29.36 | 30.4 | 33.39 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -0.39 | -2.01 | -4.45 |
| Pre-tax profit | -1.67 | -2.83 | -5.14 |